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Regulation of dauer larva development in Caenorhabditis
elegans by daf-18, a homologue of the tumour suppressor PTEN
Jean-Pierre Rouault*†, Patricia E. Kuwabara‡†, Olga M. Sinilnikova§, 
Laurent Duret¶, Danielle Thierry-Mieg¥ and Marc Billaud§
The tumour suppressor gene PTEN (also called MMAC1
or TEP1) is somatically mutated in a variety of cancer
types [1–4]. In addition, germline mutation of PTEN is
responsible for two dominantly inherited, related
cancer syndromes called Cowden disease and
Bannayan–Ruvalcaba–Riley syndrome [4]. PTEN
encodes a dual-specificity phosphatase that inhibits
cell spreading and migration partly by inhibiting
integrin-mediated signalling [5–7]. Furthermore, PTEN
regulates the levels of phosphatidylinositol 3,4,5-
trisphosphate (PIP3) by specifically dephosphorylating
position 3 on the inositol ring [8]. We report here that
the dauer formation gene daf-18 is the Caenorhabditis
elegans homologue of PTEN. DAF-18 is a component of
the insulin-like signalling pathway controlling entry into
diapause and adult longevity that is regulated by the
DAF-2 receptor tyrosine kinase and the AGE-1 PI 
3-kinase [9]. Others have shown that mutation of daf-18
suppresses the life extension and constitutive dauer
formation associated with daf-2 or age-1 mutants.
Similarly, we show that inactivation of daf-18 by 
RNA-mediated interference mimics this suppression,
and that a wild-type daf-18 transgene rescues the dauer
defect. These results indicate that PTEN/DAF-18
antagonizes the DAF-2–AGE-1 pathway, perhaps by
catalyzing dephosphorylation of the PIP3 generated by
AGE-1. These data further support the notion that
mutations of PTEN contribute to the development of
human neoplasia through an aberrant activation of the
PI 3-kinase signalling cascade.
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Results and discussion
We identified a cosmid (T07A9) and an expressed sequence
tag (EST; yk400b8) that encode a putative C. elegans homo-
logue of the mammalian PTEN gene (Figure 1a). The
C. elegans gene is located on the left arm of chromosome IV,
between daf-1 and opu-18. Complete sequence analysis of
the yk400b8 cDNA (the cDNA was kindly provided by Yuji
Kohara) revealed a 962 amino-acid open-reading frame (see
Supplementary material published with this paper on the
internet); a 180 amino-acid region of this predicted protein
has significant sequence similarity (46% identity) with the
tensin/phosphatase domain of PTEN (Figure 1b). A multi-
ple sequence alignment of PTEN homologues shows that
the phosphatase signature motifs known to be essential for
catalysis are conserved in the C. elegans PTEN homologue
(see Supplementary material); for example, one conserved
Figure 1
(a) Physical map of the C. elegans PTEN gene (Genbank accession
number AF036706). The exon–intron structure was determined by
comparing genomic DNA and cDNA sequences; the seven exons are
depicted as boxes with shading indicating the coding sequence. The
sequence of the cDNA (EMBL accession number AJ131181) showed
that the 3′ end of exon 5 is 9 bp upstream of the position predicted by
Genefinder (T07A9.6, accession number 044405). The daf-18(e1375)
mutation was identified by sequencing polymerase chain reaction
products amplified from genomic DNA isolated from daf-18(e1375)
mutant animals. This mutation was found to consist of an insertion of
30 nucleotides combined with the deletion of 2 nucleotides within
exon 4. The insertion is composed of two repeats of 11 nucleotides
(TGCGTTGACTC) and of an incomplete repeat GTTGAC.
(b) Schematic representation of the C. elegans PTEN protein. The 
daf-18 mutation results in the addition of 6 amino acids and the
formation of a stop codon (asterisk) after amino acid 563.
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sequence is HCXAGXXR (in single-letter amino-acid
code, where X represents any amino acid), which contains
the cysteine involved in forming the thiol–phosphate
bond with the substrate [10]. Constructing a phylogenetic
tree of the tensin family shows that the C. elegans PTEN
homologue is more closely related to mammalian PTEN
than to other members of this family (see Supplementary
material). Therefore, the high conservation of the cat-
alytic core sequence across evolution suggests that
C. elegans PTEN has an enzymatic activity similar to its
mammalian counterparts.
Given the capacity of PTEN to dephosphorylate PIP3 at
position 3 on the inositol ring [8], we reasoned that the
C. elegans PTEN homologue might antagonize the function
of the PI 3-kinase AGE-1 [11]. The age-1 gene is involved
in the genetic pathway controlling the formation of dauer
larvae, the rate of ageing and the resistance to oxidative and
UV stress and to thermotolerance [11–16]; mutations in 
age-1 lead to constitutive dauer formation [13–15]. There-
fore, a simple model would predict that a mutation in the
C. elegans PTEN homologue should lead to a dauer-defec-
tive phenotype — the opposite effect of age-1 mutants. Pre-
vious studies have shown that a daf-18 mutant is defective
in dauer formation, and epistatic analyses have demon-
strated that mutation of daf-18 inhibits dauer formation
caused by the age-1(m333) mutant and suppresses life-span
extension caused by age-1(hx546) [12–15]. Furthermore, the
daf-18 gene is located on chromosome IV and maps to a
region compatible with the position of the PTEN homo-
logue. On the basis of these arguments, daf-18 was consid-
ered to be an excellent candidate for the C. elegans PTEN.
We therefore sequenced the PTEN gene in the daf-18
mutant strain CB1375 and found an insertion of 30 base
pairs in exon 4 (Figure 1a) that results in the addition of six
amino acids followed by a premature stop codon immedi-
ately after amino acid 563 (Figure 1b). This mutation falls
outside the phosphatase domain and is predicted either to
truncate the PTEN/DAF-18 protein or to lead to destabi-
lization of the transcript or protein.
The daf-2 gene encodes a member of the insulin receptor
family that is implicated in the genetic pathway control-
ling dauer formation and the rate of ageing [13–20].
Genetic epistasis interactions place the daf-2(e1370, m65)
mutant upstream of daf-18 for life-span determination
[14,15]; the order of these two genes in the pathway regu-
lating dauer formation is somewhat ambiguous, however,
because daf-2(e1370) daf-18 double mutants can enter,
and rapidly exit, the dauer state [14,21]. To explore the
role of PTEN/daf-18 in the daf-2-mediated control of dia-
pause, we used RNA interference (RNAi) [22] to inacti-
vate PTEN/daf-18 expression in daf-2(e1368) and
age-1(mg44) mutants. As shown in Table 1, daf-2 mutants
from parents injected with the unrelated tra-2 double-
stranded interfering RNA (dsRNA) and grown at the
restrictive temperature arrested as dauers, whereas 68% of
those from daf-2 parents injected with PTEN/daf-18
dsRNA gave rise to adults. Similarly, RNAi inhibition of
PTEN/daf-18 in age-1(mg44) mutants resulted in an almost
complete rescue of the age-1 phenotype: 92% of the
progeny of injected worms proceeded to the adult stage
(Table 2). Finally, we showed that a wild-type daf-18
transgene is capable of rescuing daf-18 in a daf-2(e1368)
daf-18 double mutant, which is dauer-defective. In this
mutant background, the ability of a transgene to restore
dauer formation at the restrictive temperature is an indica-
tor of daf-18 rescue. As shown in Table 3, 30% of
330 Current Biology, Vol 9 No 6
Table 1
Effects of PTEN/daf-18 dsRNA injection on daf-2 dauer
formation.
Phenotype of progeny at 25.5°C (%)
RNAi N Adult Dauer Dead
Uninjected 1340 0 99 1
PTEN/daf-18 841 68 29 3
tra-2 685 0 98 2
PTEN/daf-18 dsRNA was synthesized using a subclone of the
yk400b8 cDNA as a template, and 2 mg/ml of this dsRNA was
injected into six adult daf-2(e1368) hermaphrodites. Control
daf-2(e1368) animals were left uninjected or injected with the tra-2
dsRNA. The animals were grown at the permissive temperature (15°C)
then shifted to 25.5°C after injection. They were transferred to a fresh
plate 12–18 h after injection and then subsequently transferred at 24 h
intervals. All the F1 progeny born from injected animals were scored
for phenotype, therefore the effect of RNAi was underestimated as
animals produced by eggs not affected by RNAi at the time of injection
were also scored for phenotype. N represents the total number of F1
animals scored after injection. 
Table 2
Effects of PTEN/daf-18 dsRNA injection on age-1 dauer
formation.
Phenotype of progeny at 20°C (%)
RNAi N Adult Dauer Dead
Uninjected 361 0 100 0
PTEN/daf-18 746 92 7 1
In this series of experiments, 18 non-dauer animals from an
age-1(mg44)/mnC1 strain were injected with the PTEN/daf-18 dsRNA
described in Table 1. The animals were either age-1(mg44)/mnC1 or
age-1/age-1 (m+z–, indicating the presence of the maternal and
absence of the zygotic wild-type alleles) in genotype, because the 
age-1 mutation is maternally rescued. To distinguish between these
alternative genotypes, the F1 progeny were analyzed:
age-1(mg44)/mnC1 animals produce a fraction of homozygous
uncoordinated mnC1 progeny, whereas age-1/age-1 (m+z–) parents do
not produce mnC1 progeny. In this study, 8 out of 18 of the injected
animals were age-1/age-1 (m+z–). N represents the total number of
progeny scored from the 8 injected age-1/age-1 (m+z–) parents.
daf-2(e1368) daf-18 double mutants carrying a transgene
consisting of the wild-type daf-18 gene and the visible
marker rol-6 developed into dauers at the restrictive tem-
perature (25.5°C), whereas control animals carrying only a
rol-6 transgene were unable to form dauers. Overall, these
results demonstrate that PTEN/daf-18 is epistatic to daf-2
and age-1 for the control of dauer formation and sustain
the notion that PTEN/DAF-18 has a critical function
downstream of the AGE-1 PI 3-kinase.
On the basis of these results, we propose that PTEN/DAF-
18 negatively controls the DAF-2–AGE-1–AKT pathway
and ensures a transient activation of the kinase AKT upon
stimulation of DAF-2 by its cognate ligand (Figure 2). The
high conservation of the core enzymatic domain between
PTEN/DAF-18 and mammalian PTEN supports the
notion that these enzymes recognize similar substrates and
thereby favours the idea that PTEN/DAF-18 antagonizes
AGE-1 PI 3-kinase via its PIP3 3-phosphatase activity
(Figure 2). If so, then PTEN/daf-18 lies downstream of 
age-1 and upstream of akt and the fork head transcription
factor daf-16 in the daf-2-mediated decision to enter dia-
pause. The epistatic ordering of genes involved in the daf-2
pathway that controls dauer formation can be interpreted as
a linear signalling cascade whereby daf-2, age-1, daf-18, akt
and daf-16 act within the same cell. Genetic mosaic analy-
ses have recently challenged this straightforward concep-
tion, however, by revealing that daf-2 function in the
control of dauer development and longevity is not cell-
autonomous [23]. Nevertheless, it remains very likely that
age-1, PTEN/daf-18 and akt operate within the same cells.
The observation that PTEN/daf-18 suppresses dauer forma-
tion of null alleles of age-1, such as the mg44 mutation
(which is predicted to truncate the PI 3-kinase lipid kinase
domain [11]), suggests that PIP3 might also be produced in
an AGE-1-independent manner and that disruption of
DAF-18 would raise the level of PIP3 above the threshold
required for the activation of AKT. In addition, the F1
progeny of animals injected with PTEN/daf-18 RNAi dis-
played defects in vulval development, thus indicating that
PTEN/daf-18 is likely to have a role during vulval morpho-
genesis. The nature of the daf-18(e1375) mutation suggests
that it might be hypomorphic and so the absence of other
PTEN/daf-18 alleles raises the possibility that a null muta-
tion in PTEN/daf-18 might be lethal. Although experiments
with PTEN/daf-18 RNAi have so far failed to uncover any
significantly elevated lethality, it is possible that RNAi is
unable to block PTEN/daf-18 expression completely.
Therefore, it remains important to obtain additional
PTEN/daf-18 alleles in order to determine whether this
gene plays an essential role in C. elegans development.
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Table 3
Expression of PTEN/daf-18 rescues the dauer-defective
phenotype in the daf-2(e1368) daf-18(e1375) double mutant.
Phenotype of progeny at 25.5°C (%)
Transgenes N Roller adult Roller dauer
rol6 1,166 11 1 <
PTEN/daf18 + rol6 731 13 30
The double mutant strain daf-2(e1368) daf-18(e1375) was constructed
using standard genetic methods. These double-mutant animals
developed as viable adults at the restrictive temperature (25.5°C). The
dominant transformation marker rol-6 (su1006) was singly injected in
the syncytial gonad or co-injected with 7.6 kb of genomic DNA
containing the PTEN/daf-18 gene. Transgenic roller animals were
picked, and the phenotype was scored (roller adult versus roller dauer)
after shifting the temperature from 15°C to 25.5°C. The transgene is an
extrachromosomal array that imperfectly segregates in mitosis and
meiosis, thus explaining the variation of the transmission rate. 
Figure 2
Model for the function of PTEN/DAF-18
during C. elegans dauer development. The
normal life cycle of C. elegans occurs when
the dauer pheromone is present at low
concentration. Reduced levels of the
pheromone result in the activation of the
DAF-2 receptor tyrosine kinase via the binding
of a putative insulin-like ligand. Activated
DAF-2 promotes the stimulation of AGE-1 and
the ensuing production of PIP3 which allows
the recruitment of AKT (AKT1 and AKT2) to
the plasma membrane and their subsequent
activation. AKT might directly phosphorylate
the DAF-16 transcription factor and thereby
relieve its repressor function. In this model,
PTEN/DAF-18 would antagonize AGE-1
function by catalyzing the dephosphorylation
of PIP3, thereby ensuring that activation of the
DAF-2–AGE-1 pathway is transient. 
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Dysregulation of the PI 3-kinase pathway has clearly been
involved in the transformation process mediated by various
oncogenes [24]. Also, amplification of PIK3CA, which
encodes the catalytic subunit of PI 3-kinase, has been char-
acterized in a frequent proportion of ovarian cancers, and
amplification of Akt2 has been characterized in a fraction of
ovarian, pancreatic and breast cancers [25–27]. Our data
underscore the key role that PTEN/DAF-18 might have in
the regulation of the PI 3-kinase–AKT pathway and
strongly support the notion that inactivating mutations of
PTEN in human tumours are likely to result in an aberrant
stimulation of Akt and downstream effectors — a model
substantiated by several recent studies [28–30]. While this
work was being submitted for publication, Ogg and
Ruvkun [31] also reported similar findings, namely that
DAF-18 is a C. elegans PTEN homologue that acts in the
insulin-like receptor signalling pathway.
Supplementary material
The sequence of the predicted PTEN homologue protein deduced from
the sequence of the full-length cDNA yk400b8, an alignment of the
tensin/phosphatase domain with members of the PTEN family, a phylo-
genetic tree of the tensin family, and additional methodological details
are published with this paper on the internet.
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Supplementary materials and methods
DNA sequencing of the PTEN/daf-18 gene
Worms (N2 and CB1375 daf-18(e1375) strains) were lysed in 20 µl of
lysis buffer (Tris-HCl pH 8.3, KCl 50 mM, MgCl2 2.5 mM, NP40 0.45%,
Tween 20 0.01%, gelatin 0.01% and 1 ml proteinase K at 2 mg/ml) for
1 h at 60°C. The reaction was stopped by incubation at 95°C for
15 min. The PTEN/daf-18 gene was PCR amplified with the Expand Hi-
Fidelity polymerase (Boehringer Mannheim) using five different primer
pairs (P6/P19; P5/P7; P1/P13; P10/P16; P15/P8) and 2 µl of worm
lysates. P1: 5′-AAATAGTGAATCCTCCTG-3′; P5: 5′-ACTCAA-
CAATTTCTGACC-3′; P6: 5′-ATTCTATCACACTTCACC-3′; P7: 5′-
ATTTAGCAGCCTTATCTC-3′; P8: 5′-ATTTTTCAGATTCGTCGG-3′;
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CSENLVSDFFEHRNIAVLNRYCRYFYKQRSTSRSRYPRKFRYCPLIKKHF
YIPADTDDVDENGQPFFHSPEHYIKEQEKIDAEKAAKGIENTGPSTSGSS
APGTIKKTEASQSDKVKPATEDELPPARLPDNVRRFPVVGVDFENPEEES
CEHKTVESIAGFEPLEHLFHESYHPNTAGNMLRQDYHTDSEVKIAEQEAK
AFVDQLLNGQGVLQEFMKQFKVPSDNSFADYVTGQAEVFKAQIALLEQSE
DFQRVQANAEEVDLEHTLGEAFERFGHVVEESNGSSKNPKALKTREQMVK
ETGKDTQKTRNHVLLHLEANHRVQIERRETCPELHPEDKIPRIAHFSENS
FSDSNFDQAIYL
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(a) Sequence of the predicted PTEN homologue protein in C. elegans
deduced from the sequence of the full-length cDNA yk400b8.
(b) Alignment of the tensin/phosphatase domain from members of the
PTEN family. The alignment was computed with CLUSTALW.
Identities are symbolised by a star and similarities by a dot. Dashes
indicate skipped residues. (c) Phylogenetic tree of the tensin family.
This tree was constructed using the neighbor joining method [S1],
based on the alignment of the amino-terminal part of the tensin domain
(175 sites), which is conserved in all members of the tensin family.
Bootstrap values (500 replicates) are indicated. SWISSPROT
accession numbers are as follows: for PTEN: human (O00633), mouse
(O08586), rat (O54857), C. elegans (T07A9.6, O44405); PTEN2:
human (O43460, O14781); GAK (cyclin G-associated kinase): human
(O14976), rat (P97874); TENSIN: chicken (Q04205); F46F11.3: C.
elegans hypothetical 30.3 kDa protein F46F11.3 (P91301); AUXILIN:
bovine (Q27974).
P10: 5′-CATAAACCTACTTTTTCAAC-3′; P13: 5′-CTCCATTAT-
ACTTTCCATC-3′; P15: 5′-CTTTTTATATTATATGCGGG-3′ P16: 5′-
GATACAAGAAAATAGTCACC-3′; P19: 5′-GATTTGGAGATTATGAGAG-3′.
Sequence data collection and analysis were performed on a DNA
sequencer (Model 373; Applied Biosystems) by Genome Express
(Grenoble, France).
RNAi experiments
DNA templates for in vitro transcription were linearized by digesting a
subclone of the yk400b8 cDNA clone with KpnI or SpeI. 2 µg of lin-
earized DNA template were included in an RNA synthesis reaction using
either T3 or T7 RNA polymerase, as directed by the manufacturer
(Boehringer-Mannheim), to generate sense or antisense RNA, respec-
tively. At the end of the reaction, the DNA template was digested with
RNase-free DNase, extracted with phenol : chloroform (1:1), and precip-
itated with isopropanol. The RNAs were resuspended in TE (10 mM
Tris-Cl pH 7.5; 1 mM EDTA) and mixed in equal molar ratios to generate
double-stranded RNA (dsRNA). The dsRNA was injected into the
germline syncytium of adult hermaphrodites using the methods previ-
ously described (see references in [S1]). Injected daf-2(e1368) mutants
were raised at the restrictive temperature of 25.5°C, whereas injected
age-1(mg44) mutants were raised at 20°C. Injected animals were trans-
ferred to fresh plates daily and the phenotypes of their F1 progeny were
scored by dissecting microscopy. Control injections were performed
using dsRNA corresponding to the sex-determining gene tra-2.
Transgenic strains
The 7.6 kb of genomic DNA containing the PTEN/daf-18 gene, includ-
ing 1.3 kb of upstream regulatory sequences and 1.6 kb of 3′ untrans-
lated region, was PCR amplified with the Expand Long polymerase, as
directed by the manufacturer (Boerhinger Mannheim) and using one
primer pair: ePTEN-F: 5′-GATCGCGGCCGCGATCCAA-
AAATCTCGTCGATTTTTCCG-3′; ePTEN-R: 5′-GATCGCGGCCGC-
CATTTCCCGAACGTCGATCAAAAC-3′. The PCR product was
digested with NotI, ligated into pBluescript (Stratagene) and the
plasmid DNA was bulk prepared (without cloning) after transformation
into E. Coli. Germline transformation was performed as previously
described [S2]. For rescue experiments, the pBluescript-PTEN/daf-18
vector was co-injected into daf-2(e1368) daf-18(e1375) double
mutant animals at a concentration of 20 µg/ml with the dominant roller
marker pRF4 (80 µg/ml). Transgenic roller animals were picked, and
the phenotype was scored (roller adult versus roller dauer) after shifting
the temperature from 15°C to 25.5°C.
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